First Quarter Product Revenue Increased 24% from Prior Year Quarter Three Months Ended March 31, 2024 2023 Product Revenue $38,365 $30,974 Government Contract Revenue 5,030 7,502 Total Revenue $43,395 $38,476 • The Company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to $175 million. Included in this range is full-year 2024 guidance for INTERCEPT Fibrinogen Complex, which is expected to be between $8 million to $10 million. • The Company expects to report GAAP net ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients. The trial met its primary efficacy endpoint, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs as measured by the incidence of acute kidney injury (AKI) following transfusion of study RBCs. AKI is a sensitive transfusio ...

Financial Data and Key Metrics Changes - In Q4 2023, product gross profit was $26 million, a 6% increase from $24.5 million in the prior year period, with product gross margins at 55.5%, stable compared to the previous year and slightly up from Q3 [3][14][21] - The net loss attributable to Cerus for Q4 2023 was $1.3 million, significantly improved from $13.6 million in the same period last year [63] - Non-GAAP adjusted EBITDA was positive for the first time, reaching almost $5 million, an improvement of over $8 million compared to Q4 2022 [21][60] Business Line Data and Key Metrics Changes - The U.S. product revenues in Q4 2023 exceeded prior year levels, increasing sequentially by 22% from Q3 [18][20] - The INTERCEPT Fibrinogen Complex (IFC) is expected to generate annual revenue of $8 million to $10 million in 2024, marking a significant growth opportunity [4][68] - The platelet franchise showed strong growth globally, with Canadian Blood Services implementing INTERCEPT for whole blood derived platelets, achieving over 85% of platelet units issued to hospitals being INTERCEPT treated [16][59] Market Data and Key Metrics Changes - In EMEA, Q4 product revenues were up 3% year-over-year and around 2% compared to Q3 2023, with foreign exchange rates providing a benefit of approximately 430 basis points [18] - The company anticipates continued growth in the U.S. platelet franchise and IFC business, with significant opportunities in international markets such as Germany and the Middle East [72][74] Company Strategy and Development Direction - The company is focused on international expansion of INTERCEPT platelets and growth of IFC in the U.S., with a commitment to maintaining pricing discipline amid inflation [2][74] - The strategic emphasis is on deepening relationships with existing customers and activating new accounts, particularly in the IFC business [70][72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2024, expecting double-digit growth in product revenues and improved bottom-line results [14][41] - The company is optimistic about the ReCePI trial results and anticipates providing updates on its progress throughout the year [43][91] Other Important Information - Operating expenses in Q4 2023 totaled $31.6 million, a 24% decline from $41.8 million in the prior year, reflecting the impact of a restructuring initiative [37][38] - The cash position at the end of Q4 2023 was $65.9 million, with cash used from operations at $15.2 million, compared to $1.8 million in the prior year [40][65] Q&A Session Summary Question: What is the expected revenue for IFC in 2024 and its potential market size? - The company expects IFC revenue to be in the range of $8 million to $10 million for 2024, with a total addressable market estimated between $200 million to $300 million [68][44] Question: Can you provide insights on international growth, particularly in Germany and China? - The company anticipates continued progress in Germany and sees growth opportunities in the Middle East, while the regulatory process in China is ongoing with no indication of needing a clinical trial [72][73] Question: What are the expectations for positive EBITDA in 2024? - Management indicated that positive EBITDA is a reasonable assumption for the entire year, with expectations for stability and potential improvement from Q4 levels [70][64]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-21937 CERUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 68-0262011 (State or other jurisdiction of incorporation ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences. Management plans to attend the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13th and will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6th at 11:10 AM EST. A live webcast of the TD Cowen presentation will be available here and the replay will be available on the Company’s ...

Cerus Corporation (NASDAQ:CERS) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President & Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to Cerus Corporation Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. Af ...

ITEM 1. FINANCIAL STATEMENTS 1 2 Cerus Corporation Shareholders See accompanying Notes to Condensed Consolidated Financial Statements. Note 1. Summary of Significant Accounting Policies The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related ...

Cerus Corporation (NASDAQ:CERS) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Jessica Hanover - Vice President-Corporate Affairs Obi Greenman - president and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Laurence Corash - Chief Scientific Officer Conference Call Participants Jacob Johnson - Stephens Mathew Blackman - Stifel Joshua Jennings - TD Cohen Operator Good day, ladies and gentlemen. Thank you for standing by ...

• comply with requirements established by the FDA, including post-marketing requirements and label restrictions; and • comply with other U.S. healthcare regulatory requirements. 36 We are exposed to risks associated with the highly concentrated market for the INTERCEPT Blood System. 37 Our research and development activities involve the controlled use of hazardous materials, including certain hazardous chemicals, radioactive materials and infectious pathogens, such as HIV and hepatitis viruses. Although we ...